Novavax reported $175.63M in Gross Profit on Sales for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
TG Therapeutics TGTX:US USD 77K 15K
Adma Biologics ADMA:US USD 9.66M 1.89M
AstraZeneca AZN:LN USD 8.7B 168M
Astrazeneca AZN:US USD 8.7B 168M
Biocryst Pharmaceuticals BCRX:US USD 77.05M 4.84M
Dynavax Technologies DVAX:US USD 107M 603K
GlaxoSmithKline GSK:LN GBP 5.2B 244M
Mannkind MNKD:US USD 19.93M 4.57M
Merk MRK:US USD 10.47B 610M
Moderna Inc MRNA:US USD 3.17B 902M
Novartis NVS:US USD 9.16B 21M
Novavax NVAX:US USD 175.63M 124.35M
Pfizer PFE:US USD 14.47B 2.08B
Sarepta Therapeutics SRPT:US USD 227.63M 37.31M